Deciding if Proleukin® is Appropriate for Your Patients
Clinical trials have shown that Proleukin (aldesleukin) for injection therapy has the potential, in a subset of patients, to produce a meaningful, long-lasting response.


Proleukin therapy has resulted in objective response in up to 16% of patients, with 6% to 7% of metastatic melanoma and metastatic renal cell carcinoma patients, respectively, experiencing complete and durable responses.
To assist you in evaluating your patients and determining if Proleukin therapy is appropriate. Visit the Is Your Patient a Candidate? page.